Drug Approval | January 20, 2022
Australia grants provisional registration for Novavax Covid-19 vaccine
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Nuvaxovid is the first protein-based Covid-19 vaccine to receive approval for provisional registration in Australia
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
The tie-up combines Abbisko Therapeutics’ proprietary drug discovery platform with Lilly’s disease and discovery expertise
Results from the BiologyWorks k(now) molecular test were 99.1% in overall percent agreement with the results of the RT-PCR lab tests
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
The new plant at Slovenská ?up?a site in Slovakia is scheduled to come on stream in two years
Three Indian firms namely Curisin, Immunidex and Telemedicine Indian company are part of the first phase
New data from ongoing trial showed increased antibody response against Beta, Delta, Alpha, Gamma and Omicron variants following third dose booster with Vaxzevria
KardiaMobile is the first personal ECG to be recommended by NICE for use within the National Health Service (NHS) in England and Wales
Subscribe To Our Newsletter & Stay Updated
